Henin Maged, Ragy Hany, Mannion James, David Santhosh, Refila Beshoy, Boles Usama
University Hospital Waterford, Waterford, Ireland.
National Heart Institute, Cairo, Egypt.
Cardiol Res. 2020 Feb;11(1):1-8. doi: 10.14740/cr989. Epub 2020 Jan 26.
Cardiac resynchronization therapy (CRT) benefits have been firmly established in patients with heart failure and reduced left ventricular ejection fraction (HFrEF), who remain in New York Heart Association (NYHA) functional classes II and III, despite optimal medical therapy, and have a wide QRS complex. An important and consistent finding in published systematic reviews and in subgroup analyses is that the benefits of CRT are maximum for patients with a broader QRS durations, typically described as QRS duration > 150 ms, and for patients with a typical left bundle branch block (LBBB) QRS morphology. It remains uncertain whether patients with non-LBBB QRS complex morphology clearly benefit from CRT or only modestly respond.
心脏再同步治疗(CRT)已被明确证实对心力衰竭伴左心室射血分数降低(HFrEF)的患者有益,这些患者尽管接受了最佳药物治疗,但仍处于纽约心脏协会(NYHA)心功能II级和III级,且QRS波群增宽。在已发表的系统评价和亚组分析中,一个重要且一致的发现是,对于QRS时限更宽(通常描述为QRS时限>150毫秒)的患者以及具有典型左束支传导阻滞(LBBB)QRS形态的患者,CRT的益处最大。目前尚不确定具有非LBBB QRS波群形态的患者是否能从CRT中明显获益,还是仅产生适度反应。